In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...

As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda ...

Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will ...

In Friday’s premarket trading session, Aethlon Medical, Inc. (Nasdaq: AEMD) saw its stock price rise by 5.38%, reaching $0.4110. This uptick comes amidst significant developments for the company, ...

Odd Burger Corporation ("Odd Burger" or the "Company") is pleased to announce that it intends to complete a proposed non-brokered private placement (the ??"Offering") ?up to 4,000 unsecured ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a ... make it through to market and hit commercial objectives. The deal extends an ...